MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : Nature Publishing Group, copyright 2011-
    • Subject Terms:
      Antineoplastic Agents/*therapeutic use ; Erlotinib Hydrochloride/*therapeutic use ; MAP Kinase Kinase 1/*antagonists & inhibitors ; Protein Kinase Inhibitors/*therapeutic use ; Squamous Cell Carcinoma of Head and Neck/*drug therapy; Cell Line, Tumor ; Datasets as Topic ; Drug Delivery Systems ; Drug Resistance, Neoplasm/genetics ; Epithelial-Mesenchymal Transition ; Genomics ; Humans ; Metabolic Networks and Pathways ; Phenotype ; Proteomics ; Squamous Cell Carcinoma of Head and Neck/enzymology ; Whole Genome Sequencing
    • Abstract:
      Epidermal growth factor receptor (EGFR) targeted therapies have shown limited efficacy in head and neck squamous cell carcinoma (HNSCC) patients despite its overexpression. Identifying molecular mechanisms associated with acquired resistance to EGFR-TKIs such as erlotinib remains an unmet need and a therapeutic challenge. In this study, we employed an integrated multi-omics approach to delineate mechanisms associated with acquired resistance to erlotinib by carrying out whole exome sequencing, quantitative proteomic and phosphoproteomic profiling. We observed amplification of several genes including AXL kinase and transcription factor YAP1 resulting in protein overexpression. We also observed expression of constitutively active mutant MAP2K1 (p.K57E) in erlotinib resistant SCC-R cells. An integrated analysis of genomic, proteomic and phosphoproteomic data revealed alterations in MAPK pathway and its downstream targets in SCC-R cells. We demonstrate that erlotinib-resistant cells are sensitive to MAPK pathway inhibition. This study revealed multiple genetic, proteomic and phosphoproteomic alterations associated with erlotinib resistant SCC-R cells. Our data indicates that therapeutic targeting of MAPK pathway is an effective strategy for treating erlotinib-resistant HNSCC tumors.
    • References:
      Cancer Res. 2014 Apr 15;74(8):2340-50. (PMID: 24576830)
      Cancer Lett. 2011 Jul 1;306(1):85-91. (PMID: 21411223)
      Carcinogenesis. 2012 May;33(5):956-61. (PMID: 22327936)
      Clin Cancer Res. 2009 Mar 1;15(5):1585-92. (PMID: 19190133)
      Mol Cancer Ther. 2008 Sep;7(9):2894-903. (PMID: 18790770)
      PLoS One. 2011;6(11):e27529. (PMID: 22096589)
      Blood. 2017 Jan 26;129(4):497-508. (PMID: 27756750)
      Oncologist. 2009 Sep;14(9):900-8. (PMID: 19726454)
      Nat Rev Cancer. 2004 Dec;4(12):937-47. (PMID: 15573115)
      Eur J Cancer. 2006 Jan;42(1):109-11. (PMID: 16324836)
      Target Oncol. 2015 Sep;10(3):393-404. (PMID: 25341405)
      Oncogene. 2005 Mar 17;24(12):2032-41. (PMID: 15688013)
      Cancer Treat Rev. 2017 Feb;53:61-69. (PMID: 28073102)
      Int J Clin Exp Pathol. 2013 Jul 15;6(8):1493-504. (PMID: 23923067)
      J Clin Oncol. 2006 Jun 10;24(17):2666-72. (PMID: 16763281)
      Nucleic Acids Res. 2013 Jan;41(Database issue):D1063-9. (PMID: 23203882)
      Clin Cancer Res. 2015 Apr 15;21(8):1935-43. (PMID: 25351745)
      Nucleic Acids Res. 2019 Jan 8;47(D1):D590-D595. (PMID: 30321428)
      Nat Protoc. 2009;4(1):44-57. (PMID: 19131956)
      Cancer Discov. 2016 Feb;6(2):147-153. (PMID: 26644315)
      Cancer Genet Cytogenet. 2001 Oct 1;130(1):14-21. (PMID: 11672768)
      Anticancer Res. 2011 May;31(5):1703-11. (PMID: 21617229)
      Oncol Rep. 2008 Jan;19(1):65-71. (PMID: 18097577)
      Genes Chromosomes Cancer. 2010 Jun;49(6):569-75. (PMID: 20232484)
      Bioinformatics. 2016 Jun 1;32(11):1740-2. (PMID: 26819473)
      Methods Mol Biol. 2013;1007:359-77. (PMID: 23666735)
      Mol Biotechnol. 2011 May;48(1):87-95. (PMID: 20927658)
      Sci Rep. 2016 Oct 31;6:36132. (PMID: 27796319)
      Nat Med. 2015 Jul;21(7):795-801. (PMID: 26030179)
      Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):514-9. (PMID: 9012815)
      Nat Rev Cancer. 2011 Jan;11(1):9-22. (PMID: 21160525)
      Otolaryngol Head Neck Surg. 2012 Oct;147(4):726-32. (PMID: 22568942)
      Cancer Res. 2005 Oct 15;65(20):9455-62. (PMID: 16230409)
      Oncol Rep. 2012 May;27(5):1653-9. (PMID: 22367090)
      PLoS One. 2013 Jul 31;8(7):e68966. (PMID: 23935914)
      Oncotarget. 2010 May;1(1):22-33. (PMID: 20930946)
      Oncoscience. 2018 Feb 23;5(1-2):21-38. (PMID: 29556515)
      J Cancer. 2017 Jul 20;8(12):2263-2268. (PMID: 28819429)
      PLoS One. 2016 Mar 10;11(3):e0150567. (PMID: 26962872)
      J Clin Oncol. 2004 Jan 1;22(1):77-85. (PMID: 14701768)
      Front Biosci (Landmark Ed). 2011 Jan 01;16:849-64. (PMID: 21196207)
      Cell Signal. 2007 Jul;19(7):1488-96. (PMID: 17314031)
      Cancer Res. 1988 Feb 1;48(3):589-601. (PMID: 3335022)
      Transl Lung Cancer Res. 2015 Feb;4(1):67-81. (PMID: 25806347)
      Oral Oncol. 2009 Oct;45(10):e155-60. (PMID: 19586795)
      Cancer Res. 2008 Apr 1;68(7):2391-9. (PMID: 18381447)
      J Biol Chem. 2012 Sep 7;287(37):31393-405. (PMID: 22778267)
      Mol Cancer Ther. 2013 Nov;12(11):2541-58. (PMID: 24026012)
      Nat Genet. 2012 Jun 10;44(7):783-7. (PMID: 22683711)
      Cancer Discov. 2012 May;2(5):401-4. (PMID: 22588877)
      Int J Mol Med. 2019 Jul;44(1):103-114. (PMID: 31115482)
      Cancer Res. 2008 Jul 15;68(14):5524-8. (PMID: 18632602)
      J Cell Commun Signal. 2018 Dec;12(4):709-721. (PMID: 29480433)
      Nat Genet. 2011 Dec 25;44(2):133-9. (PMID: 22197931)
      Nat Genet. 2012 Jul 01;44(8):852-60. (PMID: 22751098)
      BMC Cancer. 2006 Oct 03;6:235. (PMID: 17018150)
      Cancer Metastasis Rev. 2009 Dec;28(3-4):335-44. (PMID: 20012924)
      Nucleic Acids Res. 2009 Jan;37(1):1-13. (PMID: 19033363)
      Head Neck. 2014 Nov;36(11):1547-54. (PMID: 24123531)
      Mol Cell Proteomics. 2002 May;1(5):376-86. (PMID: 12118079)
      Nature. 2015 Jan 15;517(7534):391-5. (PMID: 25409143)
      J Biol Chem. 1998 Aug 28;273(35):22848-55. (PMID: 9712920)
      J Biol Chem. 2012 Oct 5;287(41):34091-100. (PMID: 22902619)
      PLoS One. 2014 Jan 23;9(1):e85409. (PMID: 24465552)
      Genome Res. 2017 Apr;27(4):613-625. (PMID: 28179366)
      Oncotarget. 2016 Aug 9;7(32):51922-51933. (PMID: 27409162)
      Oncotarget. 2014 May 15;5(9):2608-21. (PMID: 24810989)
      Sci Signal. 2013 Apr 02;6(269):pl1. (PMID: 23550210)
      Nat Methods. 2012 Jul;9(7):671-5. (PMID: 22930834)
      Mol Cancer Ther. 2007 Feb;6(2):532-41. (PMID: 17308052)
      Int J Oncol. 2017 Jun;50(6):2049-2058. (PMID: 28440469)
      Head Neck Oncol. 2009 Mar 02;1:6. (PMID: 19284526)
      Cancer Discov. 2012 Oct;2(10):934-47. (PMID: 22961667)
      Clin Cancer Res. 2010 May 1;16(9):2489-95. (PMID: 20406834)
      Oncotarget. 2014 Jan 30;5(2):530-43. (PMID: 24504069)
    • Accession Number:
      0 (Antineoplastic Agents)
      0 (Protein Kinase Inhibitors)
      DA87705X9K (Erlotinib Hydrochloride)
      EC 2.7.12.2 (MAP Kinase Kinase 1)
      EC 2.7.12.2 (MAP2K1 protein, human)
    • Publication Date:
      Date Created: 20191213 Date Completed: 20201106 Latest Revision: 20210110
    • Publication Date:
      20221213
    • Accession Number:
      PMC6906491
    • Accession Number:
      10.1038/s41598-019-55208-5
    • Accession Number:
      31827134